Value
7.3/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 4.7 |
| Analyst target | 9.0 |
- ▸Attractively valued
VSTM · Why this verdict
Why Verastem (VSTM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Verastem combines an elite growth-adjusted quality score, a perfect four-quarter earnings-beat streak, and 114% analyst upside, but single-product concentration risk and a risk score below the platform's floor — driven by heavy short interest and put skew — keep the setup extreme-risk despite the asymmetric reward potential.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Verastem's quality notes flag an elite Rule of 40 score (1657, driven by extreme revenue growth off a tiny base) alongside analyst price targets implying 114% upside, and the V9 panel's asymmetry ratio (5.75) cleared its 1.5 threshold. Quality breakdown | The asymmetry ratio should stay above 3.0 and analyst upside above 50% over the next 12 months as the elite growth trend continues. | →Stable |
| CounterAn elite Rule of 40 score this extreme typically reflects near-zero prior-period revenue rather than durable operating leverage, and light 8-analyst coverage makes the 114% upside estimate fragile. | ||
The bear case flags a concentration risk tied to a single product (AVMAPKI FAKZYNJA CO-PACK), a structural vulnerability for a commercial-stage biotech with one flagship therapy. Bear case | No material safety, reimbursement, or competitive setback specific to this product should occur over the next 12 months. | ↑Improving |
| CounterSingle-product concentration is inherent to early-commercial oncology biotechs and doesn't by itself indicate elevated near-term risk absent a specific negative catalyst. | ||
Verastem has beaten consensus in all 4 of the last 4 reported quarters with an average surprise of +17.7%, and the catalyst notes cite a perfect beat streak. Catalyst breakdown | The beat count should stay at 4 of 4, or at minimum not drop below 3 of 4, at the next earnings report (2026-11-03). | →Stable |
| CounterBeating deeply negative EPS estimates on a loss-making biotech is a low bar that doesn't guarantee a path to sustained profitability. | ||
The risk score (2.5) sits below the platform's 3.0 floor, driven by 22% short interest and an elevated 2.29 put/call ratio, prompting an extreme-risk-factors exit action note. Engine summary | The risk score should rise above 3.0 as short interest and put/call skew normalize over the next 12 months. | — |
| CounterElevated short interest combined with a perfect beat streak and 114% analyst upside creates meaningful short-squeeze potential that could produce a sharp positive move rather than continued deterioration. | ||
Verastem's quality notes flag an elite Rule of 40 score (1657, driven by extreme revenue growth off a tiny base) alongside analyst price targets implying 114% upside, and the V9 panel's asymmetry ratio (5.75) cleared its 1.5 threshold.
→StableQuality breakdown
- Expectation
- The asymmetry ratio should stay above 3.0 and analyst upside above 50% over the next 12 months as the elite growth trend continues.
CounterAn elite Rule of 40 score this extreme typically reflects near-zero prior-period revenue rather than durable operating leverage, and light 8-analyst coverage makes the 114% upside estimate fragile.
The bear case flags a concentration risk tied to a single product (AVMAPKI FAKZYNJA CO-PACK), a structural vulnerability for a commercial-stage biotech with one flagship therapy.
↑ImprovingBear case
- Expectation
- No material safety, reimbursement, or competitive setback specific to this product should occur over the next 12 months.
CounterSingle-product concentration is inherent to early-commercial oncology biotechs and doesn't by itself indicate elevated near-term risk absent a specific negative catalyst.
Verastem has beaten consensus in all 4 of the last 4 reported quarters with an average surprise of +17.7%, and the catalyst notes cite a perfect beat streak.
→StableCatalyst breakdown
- Expectation
- The beat count should stay at 4 of 4, or at minimum not drop below 3 of 4, at the next earnings report (2026-11-03).
CounterBeating deeply negative EPS estimates on a loss-making biotech is a low bar that doesn't guarantee a path to sustained profitability.
The risk score (2.5) sits below the platform's 3.0 floor, driven by 22% short interest and an elevated 2.29 put/call ratio, prompting an extreme-risk-factors exit action note.
—Engine summary
- Expectation
- The risk score should rise above 3.0 as short interest and put/call skew normalize over the next 12 months.
CounterElevated short interest combined with a perfect beat streak and 114% analyst upside creates meaningful short-squeeze potential that could produce a sharp positive move rather than continued deterioration.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.8 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -118% of revenue
- ▸Rule of 40: 1657 (elite)
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.2 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 90%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $111,895 (0.015% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.8 |
| quality rank | 0.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.0 |
| support resistance | 1.4 |
| 52w position | 4.0 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.4 |
| days to cover | 1.2 |
| volatility | 0.0 |
| put call | 8.4 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 3.6 |
- ▸High short interest justified: 21%
- ▸High IV: 86%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.6 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (8)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:4.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:60d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=6.0>=5.0 recovering
Reward-to-Risk
4.37
Upside
+65.6%
Downside
15.0%
Sizing output
AVOID
SetupMomentum Cont — Trend continuation, RSI 63, MACD bullish
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.7 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.8) was not enough to lift the adjusted overall above the threshold. Current asymmetry R:R is 4.37 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.8, Catalyst at 7.4, and Value at 7.3; the weakest are Technical at 2.1, Risk (lower is worse) at 4.0, and Peer rank at 4.1. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 4.37 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Rule Of 40 With Huge Upside
Trip ifAsymmetry ratio falls below 2.0, down from the current 5.75.
- P2Single Product Concentration Risk
Trip ifA material safety or reimbursement setback specific to the flagship product triggers a guidance cut exceeding 15%.
- P3Perfect Earnings Beat Streak
Trip ifBeat count drops below 3 of the trailing 4 reported quarters at the November 3, 2026 earnings report.
- P4Risk Floor Breach And Heavy Short Interest
Trip ifShort interest rises above 30% of float, up from the current 22%.